Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab plus nivolumab with prophylactic dexamethasone in advanced renal cell carcinoma
jRCTs041210108Suspended
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial of ipilimumab, nivolumab and dexamethasone in renal cell carcinoma (RCC). Primary endpoint: Incidence of grade 3 immune-related adverse events. Started Jan 2022; status: suspended.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCTs041210108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210108.